Objective: To analyze the effect of aspirin and human immunoglobulin combined therapy for Kawasaki disease.Methods: A retrospective analysis was performed on 104 patients with Kawasaki disease admitted to our hospital from January 2019 to June 2021, who were divided into a control group (n=52) and an observation group (n=52) according to treatment methods. The control group received aspirin treatment, the observation group received aspirin + human immunoglobulin treatment. The clinical efficacy, the blood indicators and immune function changes were observed. Results: The coronary artery dilation rate in the observation group was 3.85%, which was lower than that in the control group (23.08%), and fever time was shorter than that in the control group, and the difference between the 2 groups was statistically significant (P<0.05). There were no significant differences in platelet rise time, platelet rise to normal time, platelet hemostasis time and hospital stay ratio between the 2 groups (P>0.05). The peak time of platelet in observation group was significantly shorter than that in the control group (P<0.05). White blood cells (WBC) and C-reaction protein (CPR) in the observation group were lower than those in the control group after the treatment, and platelet (PLT) and erythrocyte sedimentation rate (ESR) indexes were significantly higher than those in the control group (P<0.05). Before the treatment, there was no significant difference in CD3⁺, CD4⁺ and other indexes between the 2 groups (P>0.05). After the treatment, the above immune function indexes in the observation group were higher than those in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the 2 groups (P>0.05). Conclusion: Aspirin combined with human immunoglobulin in the treatment of Kawasaki disease is effective, which can reduce the coronary artery dilation rate, and improve blood indicators and immune function level.